|
| 37679868 | SerpinA1 levels in amyotrophic lateral sclerosis patients: An exploratory study. | | 2024 |
| 36960483 | The contribution of neurofilament light chain to better characterize pediatric multiple sclerosis (editorial on: Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIK | | 2023 |
| 37668704 | Predictors for progression in amyotrophic lateral sclerosis associated to SOD1 mutation: insight from two population-based registries. | | 2023 |
| 35308898 | Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG<i>MS</i> Study. | BMJ Neurol Open | 2022 |
| 35437271 | Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset. | Neurology | 2022 |
| 34132146 | Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. | Multiple Sclerosis Journal | 2022 |
| 35296189 | Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6â¿¿years. | Multiple Sclerosis Journal | 2022 |
| 34868629 | Etiological research in pediatric multiple sclerosis: A tool to assess environmental exposures (PEDiatric Italian Genetic and enviRonment ExposurE Questionnaire). | Mult Scler J Exp Transl Clin | 2021 |
| 33938921 | Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. | JAMA Neurology | 2021 |
| 32539596 | The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. | Multiple Sclerosis Journal | 2021 |
| 32633694 | Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIG<i>MS</i> study. | Mult Scler | 2021 |
| 33221873 | In vivo gradients of thalamic damage in paediatric multiple sclerosis: a window into pathology. | Brain | 2021 |
| 33393981 | Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis. | JAMA Neurology | 2021 |
| 32552353 | Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations. | Mult Scler | 2021 |
| 32935843 | Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. | Brain | 2020 |
| 32203930 | Long-term remission of tumefactive relapsing multiple sclerosis after alemtuzumab rescue treatment in an adolescent patient. | Multiple Sclerosis and Related Disorders | 2020 |
| 32060877 | Correction to: Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSII Trials. | Neurology and Therapy | 2020 |
| 31713757 | Correction to: Aging with multiple sclerosis: prevalence and profile of cognitive impairment. | Neurological Sciences | 2020 |
| 31325110 | Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMSÂ II Trials. | Neurology and Therapy | 2019 |
| 30426289 | The Italian multiple sclerosis register. | Neurological Sciences | 2019 |
| 29363396 | Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. | Multiple Sclerosis Journal | 2019 |
| 31086807 | Different MRI patterns in MS worsening after stopping fingolimod. | Neurology: Neuroimmunology and NeuroInflammation | 2019 |
| 30867274 | Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5 year MRI study. | Neurology | 2019 |
| 31011932 | Aging with multiple sclerosis: prevalence and profile of cognitive impairment. | Neurological Sciences | 2019 |
| 30900096 | Correction to: Cognitive assessment in multiple sclerosis-an Italian consensus. | Neurological Sciences | 2019 |
| 31355324 | Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. | Neurology: Neuroimmunology and NeuroInflammation | 2019 |
| 28273776 | Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study. | Multiple Sclerosis Journal | 2018 |
| 28654357 | Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: An Italian collaborative study. | Multiple Sclerosis Journal | 2018 |
| 30315481 | European and American Guidelines for Multiple Sclerosis Treatment. | Neurology and Therapy | 2018 |
| 30207920 | Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. | N Engl J Med | 2018 |
| 29948245 | Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. | Journal of Neurology | 2018 |
| 30415358 | Authors' Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl. | Neurology and Therapy | 2018 |
| 29854416 | Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials. | Multiple Sclerosis Journal - Experimental, Translational and Clinical | 2018 |
| 29766386 | Cognitive assessment in multiple sclerosis-an Italian consensus. | Neurological Sciences | 2018 |
| 29438046 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. | Neurology | 2018 |
| 29438041 | Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks. | Neurology | 2018 |
| 28273766 | Randomized clinical trials (RCTs) in pediatric multiple sclerosis: Are they really necessary? | Multiple Sclerosis Journal | 2017 |
| 28821687 | MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients. | Neurology | 2017 |
| 28762192 | A Comprehensive Review on Copemyl. | Neurology and Therapy | 2017 |
| 28804745 | Dramatic rebounds of MS during pregnancy following fingolimod withdrawal. | Neurology: Neuroimmunology and NeuroInflammation | 2017 |
| 28831635 | A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart⿢-the FUTURE study. | Neurological Sciences | 2017 |
| 28439957 | Prognostic indicators in pediatric clinically isolated syndrome. | Annals of Neurology | 2017 |
| 29053836 | Long-term disability progression in primary progressive multiple sclerosis: a 15-year study. | Brain | 2017 |
| 29143584 | Pediatric multiple sclerosis: epidemiology, clinical aspects, diagnosis and treatment. | Neurodegenerative Disease Management | 2017 |
| 27738090 | Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. | Multiple Sclerosis Journal | 2017 |
| 27874497 | Country breakout session highlights. | Neurodegenerative Disease Management | 2016 |
| 27286847 | Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study. | Journal of Neurology | 2016 |
| 27230789 | Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies. | Multiple Sclerosis Journal | 2016 |
| 26869527 | The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis. | Multiple Sclerosis Journal | 2016 |
| 27000217 | Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study. | Journal of the Neurological Sciences | 2016 |